Strength biowaiver [Dissolution / BCS / IVIVC]

posted by Helmut Homepage – Vienna, Austria, 2018-02-25 14:20 (1858 d 19:57 ago) – Posting: # 18461
Views: 3,985

Hi powell,

I suggest:
  1. Cardot J-M, García-Arieta A, Paixão P, Taševská I, Davit B. Implementing the Biopharmaceutics Classification System in Drug Development: Reconciling Similarities, Differences, and Shared Challenges in the EMA and US-FDA-Recommended Approaches. AAPS J. 2016;18(4):1039–46. doi:10.1208/s12248-016-9915-0.
  2. Cardot J-M, García-Arieta A, Paixão P, Taševská I, Davit B. Implementing the additional strength bio­waiver for generics: EMA recommended approaches and challenges for a US-FDA submission. Eur J Pharm Sci. 2018;111:399–408. doi:10.1016/j.ejps.2017.10.013.
Both papers contain case studies.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,557 posts in 4,724 threads, 1,608 registered users;
20 visitors (0 registered, 20 guests [including 6 identified bots]).
Forum time: 11:17 CEST (Europe/Vienna)

A scientist’s aim in a discussion with his colleagues
is not to persuade, but to clarify.    Leo Szilard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5